Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-01-22 @ 11:52 AM
Study NCT ID:
NCT04777734
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2022-04-29
First Post:
2021-02-26
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efgartigimod Expanded Access for Generalized Myasthenia Gravis
Sponsor:
argenx
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ARGX-113-EAP-2101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None